TY - JOUR
T1 - Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting
AU - Moore, Caroline M.
AU - King , Lauren E.
AU - Withington, John
AU - Amin, Mahul B.
AU - Andrews, Mark
AU - Briers, Erik
AU - Chen, Ronald C.
AU - Chinegwundoh, Francis I.
AU - Cooperberg, Matthew R.
AU - Crowe, Jane
AU - Finelli, Antonio
AU - Fitch, Margaret I.
AU - Frydenberg, Mark
AU - Giganti, Francesco
AU - Haider, Masoom A.
AU - Freeman, John
AU - Gallo, Joseph
AU - Gibbs, Stephen
AU - Henry , Anthony
AU - James, Nicholas
AU - Kinsella, Netty
AU - Lam, Thomas B. L.
AU - Lichty, Mark
AU - Loeb, Stacy
AU - Mahal, Brandon A.
AU - Mastris, Ken
AU - Mitra , Anita V.
AU - Merriel, Samuel W.D.
AU - van der Kwast, Theodorus
AU - Palmer, Nynikka R.
AU - Van Hemelrijck, Mieke
AU - Paterson, Catherine C.
AU - Roobol, Monique J.
AU - Segal, Phillip
AU - Schraidt, James A.
AU - Short, Camille E.
AU - Siddiqui, M. Minhaj
AU - Tempany, Clare M.C.
AU - Villers, Arnaud
AU - Wolinsky, Howard
AU - MacLennan, Steven
PY - 2023/4
Y1 - 2023/4
N2 - BACKGROUND: Active surveillance (AS) is recommended for low-risk and some intermediate-risk prostate cancer. Uptake and practice of AS vary significantly across different settings, as does the experience of surveillance-from which tests are offered, and to the levels of psychological support. OBJECTIVE: To explore the current best practice and determine the most important research priorities in AS for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: A formal consensus process was followed, with an international expert panel of purposively sampled participants across a range of health care professionals and researchers, and those with lived experience of prostate cancer. Statements regarding the practice of AS and potential research priorities spanning the patient journey from surveillance to initiating treatment were developed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panel members scored each statement on a Likert scale. The group median score and measure of consensus were presented to participants prior to discussion and rescoring at panel meetings. Current best practice and future research priorities were identified, agreed upon, and finally ranked by panel members. RESULTS AND LIMITATIONS: There was consensus agreement that best practice includes the use of high-quality magnetic resonance imaging (MRI), which allows digital rectal examination (DRE) to be omitted, that repeat standard biopsy can be omitted when MRI and prostate-specific antigen (PSA) kinetics are stable, and that changes in PSA or DRE should prompt MRI ± biopsy rather than immediate active treatment. The highest ranked research priority was a dynamic, risk-adjusted AS approach, reducing testing for those at the least risk of progression. Improving the tests used in surveillance, ensuring equity of access and experience across different patients and settings, and improving information and communication between and within clinicians and patients were also high priorities. Limitations include the use of a limited number of panel members for practical reasons. CONCLUSIONS: The current best practice in AS includes the use of high-quality MRI to avoid DRE and as the first assessment for changes in PSA, with omission of repeat standard biopsy when PSA and MRI are stable. Development of a robust, dynamic, risk-adapted approach to surveillance is the highest research priority in AS for prostate cancer. PATIENT SUMMARY: A diverse group of experts in active surveillance, including a broad range of health care professionals and researchers and those with lived experience of prostate cancer, agreed that best practice includes the use of high-quality magnetic resonance imaging, which can allow digital rectal examination and some biopsies to be omitted. The highest research priority in active surveillance research was identified as the development of a dynamic, risk-adjusted approach.
AB - BACKGROUND: Active surveillance (AS) is recommended for low-risk and some intermediate-risk prostate cancer. Uptake and practice of AS vary significantly across different settings, as does the experience of surveillance-from which tests are offered, and to the levels of psychological support. OBJECTIVE: To explore the current best practice and determine the most important research priorities in AS for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: A formal consensus process was followed, with an international expert panel of purposively sampled participants across a range of health care professionals and researchers, and those with lived experience of prostate cancer. Statements regarding the practice of AS and potential research priorities spanning the patient journey from surveillance to initiating treatment were developed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Panel members scored each statement on a Likert scale. The group median score and measure of consensus were presented to participants prior to discussion and rescoring at panel meetings. Current best practice and future research priorities were identified, agreed upon, and finally ranked by panel members. RESULTS AND LIMITATIONS: There was consensus agreement that best practice includes the use of high-quality magnetic resonance imaging (MRI), which allows digital rectal examination (DRE) to be omitted, that repeat standard biopsy can be omitted when MRI and prostate-specific antigen (PSA) kinetics are stable, and that changes in PSA or DRE should prompt MRI ± biopsy rather than immediate active treatment. The highest ranked research priority was a dynamic, risk-adjusted AS approach, reducing testing for those at the least risk of progression. Improving the tests used in surveillance, ensuring equity of access and experience across different patients and settings, and improving information and communication between and within clinicians and patients were also high priorities. Limitations include the use of a limited number of panel members for practical reasons. CONCLUSIONS: The current best practice in AS includes the use of high-quality MRI to avoid DRE and as the first assessment for changes in PSA, with omission of repeat standard biopsy when PSA and MRI are stable. Development of a robust, dynamic, risk-adapted approach to surveillance is the highest research priority in AS for prostate cancer. PATIENT SUMMARY: A diverse group of experts in active surveillance, including a broad range of health care professionals and researchers and those with lived experience of prostate cancer, agreed that best practice includes the use of high-quality magnetic resonance imaging, which can allow digital rectal examination and some biopsies to be omitted. The highest research priority in active surveillance research was identified as the development of a dynamic, risk-adjusted approach.
KW - Active surveillance
KW - Prostate cancer
KW - Risk-adapted surveillance
UR - http://www.scopus.com/inward/record.url?scp=85152635469&partnerID=8YFLogxK
U2 - 10.1016/j.euo.2023.01.003
DO - 10.1016/j.euo.2023.01.003
M3 - Article
C2 - 36710133
AN - SCOPUS:85152635469
SN - 2588-9311
VL - 6
SP - 160
EP - 182
JO - European urology oncology
JF - European urology oncology
IS - 2
ER -